PRFX (PainReform Limited) היקף יתרות המזומנים של החברה

PainReform Ltd. (PRFX) lacks direct sales and pricing power due to the current clinical testing stage of its anesthesia formulas. Meanwhile, the modification of known molecules streamlines R&D, while the low-cost production of liquid forms under patent protection enhances operating leverage. The size of the cash reserve demonstrates a level of financial autonomy, with the latest figure standing at 0.00. The stability of future flows now depends exclusively on regulatory approval.
פילוחי מדדים פיננסיים ומדדי שוק עבור PainReform Ltd (PRFX)

This metric reflects the share of liquid reserves relative to market capitalization, determining the asset's actual protection. Analyzing this proportion helps investors assess the risk of cash flow gaps or capital management inefficiencies. The cash volume trend on the chart visualizes the company's current financial stability. For PainReform Ltd. (PRFX), a sufficient cash reserve is critical when implementing innovations in non-opioid pain management. Liquidity ensures the development of extended-release drug technologies.